Сравнение

Pemvidutide vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

Исследование на людях

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Pemvidutide	VK2735
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Pemvidutide and VK2735?: Pemvidutide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pemvidutide or VK2735?: The highest available evidence level is "Исследование на людях" for Pemvidutide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pemvidutide and VK2735 in Germany and the United States?: Германия: Pemvidutide — Не одобрено, VK2735 — Не одобрено. США: Pemvidutide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Pemvidutide

VK2735

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Pemvidutide and VK2735?

Pemvidutide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pemvidutide or VK2735?

The highest available evidence level is "Исследование на людях" for Pemvidutide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pemvidutide and VK2735 in Germany and the United States?

Германия: Pemvidutide — Не одобрено, VK2735 — Не одобрено. США: Pemvidutide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.